Wajeeha Ansari

Ms. Wajeeha Ansari

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2019 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
DNDilip Nathwani
Dilip Nathwani
DVDella Varghese
Della Varghese
JSJennifer Stephens
Jennifer Stephens
WAWajeeha Ansari
Wajeeha Ansari
SMStephan Martin
Stephan Martin
CCClaudie Charbonneau
Claudie Charbonneau
Hospital antimicrobial stewardship programs (ASPs) aim to promote judicious use of antimicrobials to combat antimicrobial resistance. For ASPs to be developed, adopted, and implemented, an economic value assessment is essential. Few studies demonstrate the cost-effectiveness of ASPs. This systematic review aimed to evaluate the economic and clinical impact of ASPs. An update to the Dik et al. systematic review (2000–2014) was conducted on EMBASE and Medline using PRISMA guidelines. The updated search was limited to primary research studies in English (30 September 2014–31 December 2017) that evaluated patient and/or economic outcomes after implementation of hospital ASPs including length of stay (LOS), antimicrobial use, and total (including operational and implementation) costs. One hundred forty-six studies meeting inclusion criteria were included. The majority of these studies were conducted within the last 5 years in North America (49%), Europe (25%), and Asia (14%), with few studies conducted in Africa (3%), South America (3%), and Australia (3%). Most studies were conducted in hospitals with 500–1000 beds and evaluated LOS and change in antibiotic expenditure, the majority of which showed a decrease in LOS (85%) and antibiotic expenditure (92%). The mean cost-savings varied by hospital size and region after implementation of ASPs. Average cost savings in US studies were $732 per patient (range: $2.50 to $2640), with similar trends exhibited in European studies. The key driver of cost savings was from reduction in LOS. Savings were higher among hospitals with comprehensive ASPs which included therapy review and antibiotic restrictions. Our data indicates that hospital ASPs have significant value with beneficial clinical and economic impacts. More robust published data is required in terms of implementation, LOS, and overall costs so that decision-makers can make a stronger case for investing in ASPs, considering competing priorities. Such data on ASPs in lower- and middle-income countries is limited and requires urgent attention.

11 November 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JHJennifer Hammond
Jennifer Hammond
HLHeidi Leister-Tebbe
Heidi Leister-Tebbe
AGAnnie Gardner
Annie Gardner
PAPaula Abreu
Paula Abreu
WBWeihang Bao
Weihang Bao
JRJames M Rusnak
James M Rusnak
Background: Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral treatment for mild to moderate coronavirus disease 2019 (COVID-19). Methods: This phase 2/3, double-blind, randomized (1:1) study assessed oral NMV/r 300 mg/100 mg versus placebo every 12 hours for 5 days in high-risk, unvaccinated, nonhospitalized, symptomatic adults with COVID-19 from 343 sites across 21 countries. In testing the primary endpoint of COVID-19‒related hospitalization and all-cause deaths and key secondary endpoints, including symptom duration and COVID-19‒related medical visits, type I error was controlled with prespecified sequential testing and the Hochberg procedure. Results: Among 2113 randomized patients enrolled from July 2021 through December 2021, 1966 (NMV/r, n = 977; placebo, n = 989) were included in the prespecified analysis population (symptom onset ≤5 days, did not receive monoclonal antibodies). NMV/r significantly reduced times to sustained alleviation (median, 13 vs 15 days; hazard ratio = 1.27, P < .0001) and resolution (16 vs 19 days; hazard ratio = 1.20, P = .0022) through day 28 and significantly reduced the number of COVID-19‒related medical visits and the proportion of patients with such visits. Hospitalized patients treated with NMV/r had shorter stays, none required intensive care unit admission or mechanical ventilation, and all were discharged to home/self-care. Fewer NMV/r-treated patients required additional treatment for COVID-19. No NMV/r-treated patients died through week 24 compared with 15 placebo-treated patients. Conclusions: In addition to reducing COVID-19‒related hospitalization or death from any cause through day 28, NMV/r was found to also reduce duration of COVID-19 symptoms and utilization of healthcare resources versus placebo in patients at high risk of progressing to severe disease. Clinical Trial Information: ClinicalTrials.gov, NCT04960202, https://clinicaltrials.gov/study/NCT04960202

2 April 2024 in Drugs - Real World Outcomes
Verified
Journal Article
Open access
PDF file
JHJennifer Hammond
Jennifer Hammond
MBMichael Benigno
Michael Benigno
NBNataly Bleibdrey
Nataly Bleibdrey
WAWajeeha Ansari
Wajeeha Ansari
JNJennifer L. Nguyen
Jennifer L. Nguyen
Background and Objective Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia results in substantial morbidity and mortality. As current treatments often lead to unsatisfactory outcomes, evidence guiding alternative treatment options is needed. This study evaluated real-world clinical outcomes of ceftaroline fosamil for the treatment of MRSA bacteremia. Methods This retrospective study included adults hospitalized with MRSA bacteremia between 2011 and 2019. Patients were classified according to treatment with ceftaroline fosamil (ceftaroline), vancomycin, or daptomycin: Group 1, ceftaroline; Group 2, vancomycin or daptomycin (without ceftaroline); Group 3, combination therapy with ≥ 2 of these three agents. Clinical outcomes were compared using propensity-score-adjusted odds ratios (ORs) from logistic regression models. Results Overall, 24,479 patients were included (Group 1, n = 532; Group 2, n = 21,555; Group 3, n = 2392). Mean age was 59.6, 60.8, and 57.4 years in Groups 1, 2, and 3, respectively. Mean post-index treatment length of stay was 8.8, 8.8, and 8.0 days, respectively. The most frequent line of therapy was ceftaroline first-line (42.1%), vancomycin or daptomycin first-line (95.4%), and combination therapy third-line or later (67.8%) in Groups 1, 2, and 3, respectively. Compared with Group 2, Groups 1 and 3 had similar favorable clinical responses {odds ratio [OR] = 1.18 [95% confidence interval (CI) 0.98–1.44], p = 0.08; OR = 1.20 [95% CI 0.97–1.47], p = 0.09, respectively} and were less likely to switch treatment (both p < 0.001). Compared with Group 2, Group 1 was more likely to undergo 30-day all-cause readmission [OR = 1.38 (95% CI 1.06–1.80), p = 0.02], whereas this was less likely for Group 3 [OR = 0.77 (95% CI 0.58–1.00), p = 0.05]. Conclusions Patients receiving ceftaroline more often had favorable clinical responses than those receiving vancomycin or daptomycin monotherapy. In the absence of large-scale randomized controlled trials, these real-world data provide insights into the potential role of ceftaroline for treating MRSA bacteremia.

31 July 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
WAWajeeha Ansari
Wajeeha Ansari
HCHenriette Coetzer
Henriette Coetzer
KGKelly A Gebo
Kelly A Gebo
JRJinma Ren
Jinma Ren
ASAmie Scott
Amie Scott
HLHeidi Leister-Tebbe
Heidi Leister-Tebbe
Background: Nirmatrelvir/ritonavir (NMV/r) is an antiviral treatment for COVID-19. We describe patient-reported outcomes with NMV/r in nonhospitalized adults with COVID-19 at high risk of severe disease. Methods: In a phase 2/3 double-blind study, high-risk adults with SARS-CoV-2 and ≤5 days of symptoms were randomized 1:1 to receive NMV/r or placebo twice daily for 5 days. Patients recorded responses to 3 Global Impression Questions (GIQs) daily through day 28 to assess return to usual health, return to usual activities, and overall severity of COVID-19-related symptoms. The COVID-19-specific Work Productivity and Activity Impairment Questionnaire (WPAI-COVID-19) and EuroQol Quality of Life 5-dimension 5-level scale (EQ-5D-5L) were completed at specified visits through week 24. Results: Compared with placebo, patients receiving NMV/r had a significant 3-day reduction in median time to return to usual health (hazard ratio [HR], 1.3; 95% confidence interval [CI], 1.2‒1.4; P < .0001), 1-day reduction in median time to return to usual activities (HR, 1.2; 95% CI, 1.1‒1.4; P < .0001), and significantly shorter GIQ times to sustained resolution of any overall symptoms (HR, 1.2; 95% CI, 1.1‒1.3; P = .0002) and sustained alleviation of any overall symptoms (HR, 1.2; 95% CI, 1.1‒1.3; P < .0001). There were no significant differences between treatment groups in the WPAI-COVID-19 or EQ-5D-5L results. Conclusions: Patients receiving NMV/r for COVID-19 reported a reduced duration and severity of COVID-19 symptoms based on their global impression of overall symptom burden and quicker return to usual health and usual activities compared with those receiving placebo. Clinical Trial Information: ClinicalTrials.gov, NCT04960202, https://clinicaltrials.gov/study/NCT04960202

6 May 2024 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
PDF file
ASAlex Soriano
Alex Soriano
MBMatteo Bassetti
Matteo Bassetti
CGCharalambos Gogos
Charalambos Gogos
TFTristan Ferry
Tristan Ferry
RPRaul de Pablo
Raul de Pablo
Francesco BlasiFrancesco Blasi
Francesco Blasi
This multicentre, observational, retrospective chart review study assessed ceftaroline fosamil treatment patterns and outcomes in adults hospitalized with community-acquired pneumonia (CAP) in usual care settings. Anonymized patient data were extracted from hospital records of adults with CAP who received ≥4 consecutive IV ceftaroline fosamil doses at sites in Brazil, Colombia, France, Greece, Italy, Russia and Spain. The dataset included 185 patients (58.9% male; mean age 62.2 years), of whom 128 (69.2%) had severe CAP defined by CURB-65, PSI/PORT score or physician judgement. Streptococcus pneumoniae (n = 44; 23.8%) and Staphylococcus aureus [MSSA (n = 15) and MRSA (n = 14)] were the most frequently identified pathogens. Clinical response occurred in 151 (81.6%) patients overall, and in 104 (81.3%) severe CAP patients. Response within ≤4 and >4 days occurred in 79 (42.7%) and 62 (33.5%) patients (unknown, n = 10), respectively. Twenty (10.8%) patients required readmission within 30 days. Thirty-day all-cause mortality rates were 9.7% (n = 18) overall and 10.2% (n = 13) in severe CAP. In sensitivity analysis using ICU admission as a more objective marker of severe CAP (n = 75), clinical response and 30 day mortality occurred in 57 (76.0%) and 10 (13.3%) patients, respectively. Overall, clinical response to ceftaroline fosamil was associated with >60% shorter length of ICU stay (3.6 versus 9.2 days), and >30% lower hospital costs ($8449 versus $12 559) versus non-responders. Ceftaroline fosamil was effective in treating adults with CAP, including severe CAP, in Europe and Latin America. Clinical response to ceftaroline fosamil was associated with reductions in healthcare resource use compared with non-responders.

1 January 2022 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
ATAntoni Torres
Antoni Torres
ASAlex Soriano
Alex Soriano
SRSimone Rivolo
Simone Rivolo
EREdit Remak
Edit Remak
CPCarmen Peral
Carmen Peral
MWMark Wilcox
Mark Wilcox
Purpose: Complicated skin and soft tissue infections (cSSTI) are associated with high healthcare resource use and costs. The emergency nature of cSSTI hospitalizations requires starting immediate empiric intravenous (IV) antibiotic treatment, making the appropriate choice of initial antibiotic therapy crucial. Patients and Methods: The use of ceftaroline fosamil (CFT) as an alternative to other IV antibiotic therapies for the empiric treatment of hospitalized adults with cSSTI (vancomycin, linezolid, daptomycin, cloxacillin, tedizolid) was evaluated through cost consequences analysis. The model structure was a decision tree accounting for four different pathways: patients demonstrating early response (ER) either discharged early (with oral antibiotic) or remaining in hospital to continue the initial therapy; non-responders either remaining on the initial IV therapy or switching to a second-line antibiotic. The model perspective was the Spanish National Health System. Results: CFT resulted in average percentage of patients discharged early (PDE) of 24.6% (CI 19.49-30.2%) with average total cost per patient of (sic)6763 ((sic)6268-(sic)7219). Vancomycin, linezolid, daptomycin and tedizolid resulted in average PDE of 22% (17.34-27.09%), 26.4% (20.5-32.32%), 28.6% (22.08-35.79%) and 26.5% (20.39-33.25%), respectively, for a total cost per patient of (sic)6,619 ((sic)5,902-(sic)6,929), (sic)6,394 ((sic)5,881-(sic)6,904), (sic)6,855 ((sic)5,800-(sic)7,410) and (sic)7,173 ((sic)6,608-(sic)7,763), respectively. Key model drivers were ER and antibiotic treatment duration, with hospital costs accounting for over 83% of the total expenditures. Conclusion: Given its clinical and safety profile, CFT is an acceptable choice for cSSTI empiric therapy providing comparable ER and costs to other relevant antibiotic options.